Besides, subsequent exploration suggested that TRIM9 shRNA treatment resulted in increased mRNA and protein expression of stem-like phenotypic biomarkers on tumor cells, including CD133 and CD44, whereas TRIM9 overexpression demonstrated completely opposite effects (Figures 3(e) and 3(f)). This evidence concerns the gene PROM1 and neoplasm.